Making light work of bacterial infections
We will create a light-activated, topical product to kill bacteria in infected wounds which fits into the current standard of care. We can kill resistant bacteria and bacteria cannot generate resistance towards our treatment modality.
Advantages over other light-activated anti-infection modalities:
– LightOx own all of our compounds and can make desired changes using in-house chemistry team
– Compounds are activated by a simple, low-cost LED device
– Our treatment is amenable to non-hospital settings, can be taken into the community
Advantages over conventional dressing antimicrobials:
– LightOx compounds are non-cytotoxic without light (>50 fold IC50) meaning little off-target effects.
- Antimicrobial compound/strategy
- Infection prevention
- Antimicrobial stewardship
- Microbial diagnostics
- Removal antibiotics/bacteria
- Market entry
- Marketed product
- Joint Venture
- OTHER / NA
Infectious disease area:
- North America
- South America
LightOx develop light based solutions for clinical problems. Our platform technology has wide ranging applications.
Our technology is effective at killing bacteria, including those resistant to traditional antibiotics (e.g. MRSA). This work is funded by two Innovate UK grants. We are compiling a pre-clinical data package for an infected chronic wound product. We envisage a topical gel product which fits into the standard of care currently used, leading to fewer bandage changes required for chronic wounds e.g. diabetic foot ulcers.
Another project in our portfolio is a light-based, topical treatment for oral epithelial dysplasia, funded by Innovate UK. Our therapeutic (LXD191) is currently in formulation and will be entering Phase I clinical trials in 2024/25 with our clinical team at Liverpool Head and Neck Centre.
Showcasing the versatility of our technology, Health Holland fund a project creating antibody-drug conjugates to treat scleroderma with our partners at Radboudumc.
We are creating a light-based, topical treatment for oral epithelial dysplasia (OED). Current treatments for OED are limited to surgery, laser ablation, and active surveillance. Our therapeutic (LXD191) is currently in formulation and will be entering Phase I clinical trials in 2024/25 with our clinical team at Liverpool Head and Neck Centre.
LightOx technology is amenable to antibody conjugation and we are creating ADCs to treat scleroderma with our partners at Radboudumc.